tbi

TBI-223, an orally bioavailable oxazolidinone antibiotic, exhibits potent antimicrobial activity against Mycobacterium tuberculosis (Mtb)[1][2].

TBI-166, an orally active riminophenazine analogue, serves as an anti-tuberculosis agent and exhibits fewer adverse reactions compared to its lead compound, Clofazimine [1] [2] [3].

tBID is a selective homeodomain-interacting protein kinase 2 (HIPK2) inhibitor (IC50 of 0.33 µM)

TBIA (trans-bis-isatoic anhydride) is a bifunctional SHAPE (selective 2'-hydroxyl acylation analyzed by primer extension) chemical cross-linking reagent.

Etbicyphat (Trimethylopropane phosphate), a potent competitive antagonist of GABA(A) receptors, binds to GABA(A)-benzodiazepine receptors and induces epileptiform activities in hippocampal CA1 neurons.

MTOB (α-keto-γ-Methylthiobutyric acid) is a substrate for c-terminal binding protein (CtBP) that interferes with the carcinogenic activity of CtBP in cell culture and mice. It also actively regulates TCF-4 signaling, leading to cancer stem cell (CSC) growth and self-renewal.

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

The P7C3 class of neuroprotective aminopropyl carbazoles has been shown to block neuronal cell death in models of neurodegeneration. We now show that P7C3 molecules additionally preserve axonal integrity after injury, before neuronal cell death occurs, in

RX 801077 (2 BFI free base), a selective imidazoline I2 receptor (I2R) agonist with a K_i value of 70.1 nM, demonstrates anti-inflammatory and neuroprotective properties, making it a potential research candidate for traumatic brain injury (TBI).

NA-184, a selective calpain-2 inhibitor, prevents TBI-induced cell death with an EC50 of 0.13 mg kg [1].